{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T20:53:55Z","timestamp":1770670435189,"version":"3.49.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Taishan Scholars Program of Shandong Province","award":["tstp20221158"],"award-info":[{"award-number":["tstp20221158"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82073200"],"award-info":[{"award-number":["82073200"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Major basic research of Shandong Provincial Natural Science Foundation","award":["ZR2021ZD26"],"award-info":[{"award-number":["ZR2021ZD26"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"DOI":"10.1007\/s00432-025-06082-4","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T19:38:52Z","timestamp":1739302732000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparison of tenofovir versus entecavir for preventing hepatocellular carcinoma in chronic hepatitis B patients: an umbrella review and meta-analysis"],"prefix":"10.1007","volume":"151","author":[{"given":"Shi-Jia","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lun-Jie","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han-Chao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi-Niu","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo-Qiang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Long","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bao-Wen","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhao-Ru","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Xu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Chuan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,11]]},"reference":[{"issue":"3","key":"6082_CR1","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1097\/xeb.0000000000000055","volume":"13","author":"E Aromataris","year":"2015","unstructured":"Aromataris E, Fernandez R, Godfrey CM, Holly C, Khalil H, Tungpunkom P (2015) Summarizing systematic reviews: methodological development, conduct and reporting of an umbrella review approach. Int J Evid Based Healthc 13(3):132\u2013140. https:\/\/doi.org\/10.1097\/xeb.0000000000000055","journal-title":"Int J Evid Based Healthc"},{"issue":"5","key":"6082_CR2","doi-asserted-by":"publisher","first-page":"816","DOI":"10.3346\/jkms.2005.20.5.816","volume":"20","author":"SH Bae","year":"2005","unstructured":"Bae SH, Yoon SK, Jang JW et al (2005) Hepatitis B virus genotype C prevails among chronic carriers of the virus in Korea. J Korean Med Sci 20(5):816\u2013820. https:\/\/doi.org\/10.3346\/jkms.2005.20.5.816","journal-title":"J Korean Med Sci"},{"issue":"1","key":"6082_CR3","doi-asserted-by":"publisher","first-page":"e13983","DOI":"10.1097\/md.0000000000013983","volume":"98","author":"D Cai","year":"2019","unstructured":"Cai D, Pan C, Yu W et al (2019) Comparison of the long-term efficacy of tenofovir and entecavir in nucleos(t)ide analogue-na\u00efve HBeAg-positive patients with chronic hepatitis B: a large, multicentre, randomized controlled trials. Medicine (Baltimore) 98(1):e13983. https:\/\/doi.org\/10.1097\/md.0000000000013983","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"6082_CR59","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/s41598-020-80523-7","volume":"11","author":"TS Chang","year":"2021","unstructured":"Chang T-S, Yang Y-H, Chen W-M, Shen C-H, Tung S-Y, Yen C-W, Hsieh Y-Y, Lee C-P, Tsai M-L, Hung C-H, Lu S-N (2021) Long-term risk of primary liver cancers in entecavir versus tenofovir treatment for chronic hepatitis B. Sci Rep 11(1):1365. https:\/\/doi.org\/10.1038\/s41598-020-80523-7","journal-title":"Sci Rep"},{"issue":"1","key":"6082_CR4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jama.295.1.65","volume":"295","author":"CJ Chen","year":"2006","unstructured":"Chen CJ, Yang HI, Su J et al (2006) Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295(1):65\u201373. https:\/\/doi.org\/10.1001\/jama.295.1.65","journal-title":"JAMA"},{"issue":"11","key":"6082_CR60","first-page":"3882","volume":"10","author":"CH Chen","year":"2020","unstructured":"Chen CH, Chen CY, Wang JH et al (2020) Comparison of incidence of hepatocellular carcinoma between chronic hepatitis B patients with cirrhosis treated with entecavir or tenofovir in Taiwan - a retrospective study. Am J Cancer Res 10(11):3882\u20133895","journal-title":"Am J Cancer Res"},{"issue":"10","key":"6082_CR5","doi-asserted-by":"publisher","first-page":"e00236","DOI":"10.14309\/ctg.0000000000000236","volume":"11","author":"KS Cheung","year":"2020","unstructured":"Cheung KS, Mak LY, Liu SH et al (2020) Entecavir vs tenofovir in hepatocellular carcinoma prevention in chronic hepatitis B infection: a systematic review and meta-analysis. Clin Transl Gastroenterol 11(10):e00236. https:\/\/doi.org\/10.14309\/ctg.0000000000000236","journal-title":"Clin Transl Gastroenterol"},{"key":"6082_CR61","first-page":"268A","volume":"68","author":"BW Cho","year":"2018","unstructured":"Cho BW, Jang JW, Chae HB, Kim SB, Song IH (2018) Long-term clinical outcomes of chronic hepatitis B patients treated with entecavir vs. tenofovir: a retrospective, observational, comparative study. Hepatology 68:268A","journal-title":"Hepatology"},{"issue":"4","key":"6082_CR6","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.jhep.2019.06.013","volume":"71","author":"J Choi","year":"2019","unstructured":"Choi J, Lim YS (2019) Comparison of risk of hepatocellular carcinoma between tenofovir and entecavir: One direction or no direction. J Hepatol 71(4):846\u2013847. https:\/\/doi.org\/10.1016\/j.jhep.2019.06.013","journal-title":"J Hepatol"},{"issue":"1","key":"6082_CR7","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1001\/jamaoncol.2018.4070","volume":"5","author":"J Choi","year":"2019","unstructured":"Choi J, Kim HJ, Lee J, Cho S, Ko MJ, Lim YS (2019) Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: a Korean nationwide cohort study. JAMA Oncol 5(1):30\u201336. https:\/\/doi.org\/10.1001\/jamaoncol.2018.4070","journal-title":"JAMA Oncol"},{"issue":"2","key":"6082_CR8","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.cgh.2020.05.008","volume":"19","author":"WM Choi","year":"2021","unstructured":"Choi WM, Choi J, Lim YS (2021) Effects of tenofovir vs entecavir on risk of hepatocellular carcinoma in patients with chronic HBV infection: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 19(2):246-258.e9. https:\/\/doi.org\/10.1016\/j.cgh.2020.05.008","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"6082_CR9","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.jhep.2021.09.017","volume":"76","author":"WM Choi","year":"2022","unstructured":"Choi WM, Yip TC, Lim YS, Wong GL, Kim WR (2022) Methodological challenges of performing meta-analyses to compare the risk of hepatocellular carcinoma between chronic hepatitis B treatments. J Hepatol 76(1):186\u2013194. https:\/\/doi.org\/10.1016\/j.jhep.2021.09.017","journal-title":"J Hepatol"},{"issue":"1","key":"6082_CR10","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/hep.31267","volume":"73","author":"S Dave","year":"2021","unstructured":"Dave S, Park S, Murad MH et al (2021) Comparative effectiveness of entecavir versus tenofovir for preventing hepatocellular carcinoma in patients with chronic hepatitis B: a systematic review and meta-analysis. Hepatology 73(1):68\u201378. https:\/\/doi.org\/10.1002\/hep.31267","journal-title":"Hepatology"},{"issue":"8","key":"6082_CR11","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1111\/hepr.13504","volume":"50","author":"Drafting Committee for Hepatitis Management Guidelines","year":"2020","unstructured":"Drafting Committee for Hepatitis Management Guidelines (2020) Japan society of hepatology guidelines for the management of hepatitis B virus infection: 2019 update. Hepatol Res 50(8):892\u2013923. https:\/\/doi.org\/10.1111\/hepr.13504","journal-title":"Hepatol Res"},{"issue":"2","key":"6082_CR12","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"EASL","year":"2017","unstructured":"EASL (2017) Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol 67(2):370\u2013398. https:\/\/doi.org\/10.1016\/j.jhep.2017.03.021","journal-title":"J Hepatol"},{"issue":"6","key":"6082_CR13","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1053\/j.gastro.2011.12.061","volume":"142","author":"HB El-Serag","year":"2012","unstructured":"El-Serag HB (2012) Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142(6):1264-1273.e1. https:\/\/doi.org\/10.1053\/j.gastro.2011.12.061","journal-title":"Gastroenterology"},{"issue":"3","key":"6082_CR14","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1136\/ebmental-2018-300014","volume":"21","author":"P Fusar-Poli","year":"2018","unstructured":"Fusar-Poli P, Radua J (2018) Ten simple rules for conducting umbrella reviews. Evid Based Ment Health 21(3):95\u2013100. https:\/\/doi.org\/10.1136\/ebmental-2018-300014","journal-title":"Evid Based Ment Health"},{"issue":"1","key":"6082_CR62","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/S0618-8278(19)30259-2","volume":"70","author":"SC Gordon","year":"2019","unstructured":"Gordan SC, Zhou Y, Li J (2019) LBP-13-Effect of treatment of hepatitis B patients with tenofovir disoproxil or entecavir on risk of hepatocellular cancer death in a U.S. Cohort. J Hepatol 70(1):e147. https:\/\/doi.org\/10.1016\/S0618-8278(19)30259-2","journal-title":"J Hepatol"},{"issue":"9","key":"6082_CR15","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1111\/jgh.15036","volume":"35","author":"L Gu","year":"2020","unstructured":"Gu L, Yao Q, Shen Z et al (2020) Comparison of tenofovir versus entecavir on reducing incidence of hepatocellular carcinoma in chronic hepatitis B patients: a systematic review and meta-analysis. J Gastroenterol Hepatol 35(9):1467\u20131476. https:\/\/doi.org\/10.1111\/jgh.15036","journal-title":"J Gastroenterol Hepatol"},{"issue":"7650","key":"6082_CR16","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE et al (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336(7650):924\u2013926. https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD","journal-title":"BMJ"},{"issue":"4","key":"6082_CR63","doi-asserted-by":"publisher","first-page":"412","DOI":"10.5152\/tjg.2021.20423","volume":"32","author":"F G\u00fczelbulut","year":"2021","unstructured":"G\u00fczelbulut F, G\u00f6k\u00e7en P, Can G, Adal\u0131 G, De\u011firmenci Salt\u00fcrk AG, Aslan E, \u00d6zdil K, Do\u011fanay HL (2021) Comparison of the efficacy of entecavir and tenofovir in reducing hepatocellular carcinoma risk in chronic hepatitis B patients: a real-life study in Turkey. Turk J Gastroenterol 32(4):412\u2013421. https:\/\/doi.org\/10.5152\/tjg.2021.20423","journal-title":"Turk J Gastroenterol"},{"issue":"10","key":"6082_CR64","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1111\/jgh.15031","volume":"35","author":"I Ha","year":"2020","unstructured":"Ha I, Chung JW, Jang ES, Jeong SH, Kim JW (2020a) Comparison of the on-treatment risks for hepatocellular carcinoma between entecavir and tenofovir: a propensity score matching analysis. J Gastroenterol Hepatol 35(10):1774\u20131781. https:\/\/doi.org\/10.1111\/jgh.15031","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"6082_CR65","doi-asserted-by":"publisher","first-page":"13537","DOI":"10.1038\/s41598-020-70433-z","volume":"10","author":"Y Ha","year":"2020","unstructured":"Ha Y, Chon YE, Kim MN, Lee JH, Hwang SG (2020b) Hepatocellular carcinoma and death and transplantation in chronic hepatitis B treated with entecavir or tenofovir disoproxil fumarate. Sci Rep 10(1):13537. https:\/\/doi.org\/10.1038\/s41598-020-70433-z","journal-title":"Sci Rep"},{"issue":"1","key":"6082_CR17","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/hep.26180","volume":"58","author":"T Hosaka","year":"2013","unstructured":"Hosaka T, Suzuki F, Kobayashi M et al (2013) Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 58(1):98\u2013107. https:\/\/doi.org\/10.1002\/hep.26180","journal-title":"Hepatology"},{"issue":"2","key":"6082_CR18","doi-asserted-by":"publisher","first-page":"271","DOI":"10.14309\/ajg.0000000000000428","volume":"115","author":"YC Hsu","year":"2020","unstructured":"Hsu YC, Wong GL, Chen CH et al (2020) Tenofovir versus entecavir for hepatocellular carcinoma prevention in an international consortium of chronic hepatitis B. Am J Gastroenterol 115(2):271\u2013280. https:\/\/doi.org\/10.14309\/ajg.0000000000000428","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"6082_CR66","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1111\/apt.16116","volume":"52","author":"TH Hu","year":"2020","unstructured":"Hu TH, Yueh-Hsia Chiu S, Tseng PL et al (2020) Five-year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment-na\u00efve patients with chronic hepatitis B-related compensated cirrhosis in Taiwan. Aliment Pharmacol Ther 52(11-12):1695\u20131706. https:\/\/doi.org\/10.1111\/apt.16116","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"6082_CR19","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s40001-023-01075-w","volume":"28","author":"S Jaff","year":"2023","unstructured":"Jaff S, Zeraattalab-Motlagh S, Amiri Khosroshahi R, Gubari M, Mohammadi H, Djafarian K (2023) The effect of selenium therapy in critically ill patients: an umbrella review of systematic reviews and meta-analysis of randomized controlled trials. Eur J Med Res 28(1):104. https:\/\/doi.org\/10.1186\/s40001-023-01075-w","journal-title":"Eur J Med Res"},{"issue":"6","key":"6082_CR20","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1016\/j.cgh.2021.09.001","volume":"20","author":"H Jang","year":"2022","unstructured":"Jang H, Yoon JS, Park SY et al (2022) Impact of HBeAg on hepatocellular carcinoma risk during oral antiviral treatment in patients with chronic hepatitis B. Clin Gastroenterol Hepatol 20(6):1343-1353.e16. https:\/\/doi.org\/10.1016\/j.cgh.2021.09.001","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"6082_CR21","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1111\/jvh.12971","volume":"25","author":"BG Kim","year":"2018","unstructured":"Kim BG, Park NH, Lee SB et al (2018a) Mortality, liver transplantation and hepatic complications in patients with treatment-na\u00efve chronic hepatitis B treated with entecavir vs tenofovir. J Viral Hepat 25(12):1565\u20131575. https:\/\/doi.org\/10.1111\/jvh.12971","journal-title":"J Viral Hepat"},{"issue":"6","key":"6082_CR67","doi-asserted-by":"publisher","first-page":"326","DOI":"10.4103\/sjg.SJG_49_18","volume":"24","author":"YM Kim","year":"2018","unstructured":"Kim YM, Shin HP, Lee JI, Joo KR, Cha JM, Jeon JW, Yoon JY, Kwak MS (2018b) Real-world single-center experience with entecavir and tenofovir disoproxil fumarate in treatment-na\u00efve and experienced patients with chronic hepatitis B. Saudi J Gastroenterol 24(6):326\u2013335. https:\/\/doi.org\/10.4103\/sjg.SJG_49_18","journal-title":"Saudi J Gastroenterol"},{"key":"6082_CR22","first-page":"302A","volume":"70","author":"W Kim","year":"2019","unstructured":"Kim W, Telep L, Lu M et al (2019a) Risk of incident hepatocellular carcinoma in hepatitis B-infected patients treated with tenofovir disoproxil fumarate versus entecavir: a US administrative claims analysis. Hepatology 70:302A-303A","journal-title":"Hepatology"},{"issue":"3","key":"6082_CR23","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jhep.2019.03.028","volume":"71","author":"SU Kim","year":"2019","unstructured":"Kim SU, Seo YS, Lee HA et al (2019b) A multicenter study of entecavir vs. tenofovir on prognosis of treatment-na\u00efve chronic hepatitis B in South Korea. J Hepatol 71(3):456\u2013464. https:\/\/doi.org\/10.1016\/j.jhep.2019.03.028","journal-title":"J Hepatol"},{"key":"6082_CR68","doi-asserted-by":"publisher","first-page":"335A","DOI":"10.1016\/j.jhep.2019.03.028","volume":"62","author":"JR Kramer","year":"2015","unstructured":"Kramer JR, Mittal S, Richardson P, El-Serag HB, Kanwal F (2015) Comparative effectiveness of tenofovir vs. entecavir in reducing the risk of hepatocellular carcinoma in a U.S. cohort of patients with chronic hepatitis B virus infection. Hepatology 62:335A\u2013336A","journal-title":"Hepatology"},{"key":"6082_CR69","first-page":"578A","volume":"70","author":"CJ Lee","year":"2019","unstructured":"Lee CJ, Su CW, Lin HC, Hou MC, Huang YH (2019) Occurrence of hepatocellular carcinoma in chronic hepatitis B patients undergoing entecavir or tenofovir treatment. Hepatology  70:578A\u2013579A","journal-title":"Hepatology"},{"issue":"7","key":"6082_CR24","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1136\/gutjnl-2019-318947","volume":"69","author":"SW Lee","year":"2020","unstructured":"Lee SW, Kwon JH, Lee HL et al (2020) Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-na\u00efve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis. Gut 69(7):1301\u20131308. https:\/\/doi.org\/10.1136\/gutjnl-2019-318947","journal-title":"Gut"},{"issue":"3","key":"6082_CR25","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3350\/cmh.2021.0179","volume":"27","author":"SW Lee","year":"2021","unstructured":"Lee SW, Choi J, Kim SU, Lim YS (2021) Entecavir versus tenofovir in patients with chronic hepatitis B: enemies or partners in the prevention of hepatocellular carcinoma. Clin Mol Hepatol 27(3):402\u2013412. https:\/\/doi.org\/10.3350\/cmh.2021.0179","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"6082_CR26","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s12072-019-10005-0","volume":"14","author":"M Li","year":"2020","unstructured":"Li M, Lv T, Wu S et al (2020) Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: a critical systematic review and meta-analysis. Hepatol Int 14(1):105\u2013114. https:\/\/doi.org\/10.1007\/s12072-019-10005-0","journal-title":"Hepatol Int"},{"issue":"4","key":"6082_CR27","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1159\/000507253","volume":"9","author":"H Liu","year":"2020","unstructured":"Liu H, Shi Y, Hayden JC, Ryan PM, Rahmani J, Yu G (2020) Tenofovir treatment has lower risk of hepatocellular carcinoma than entecavir treatment in patients with chronic hepatitis B: a systematic review and meta-analysis. Liver Cancer 9(4):468\u2013476. https:\/\/doi.org\/10.1159\/000507253","journal-title":"Liver Cancer"},{"issue":"10","key":"6082_CR28","doi-asserted-by":"publisher","first-page":"e0222221","DOI":"10.1371\/journal.pone.0222221","volume":"14","author":"TL Ma","year":"2019","unstructured":"Ma TL, Hu TH, Hung CH, Wang JH, Lu SN, Chen CH (2019) Incidence and predictors of retreatment in chronic hepatitis B patients after discontinuation of entecavir or tenofovir treatment. PLoS ONE 14(10):e0222221. https:\/\/doi.org\/10.1371\/journal.pone.0222221","journal-title":"PLoS ONE"},{"issue":"2","key":"6082_CR29","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","volume":"68","author":"JA Marrero","year":"2018","unstructured":"Marrero JA, Kulik LM, Sirlin CB et al (2018) Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases. Hepatology 68(2):723\u2013750. https:\/\/doi.org\/10.1002\/hep.29913","journal-title":"Hepatology"},{"issue":"2","key":"6082_CR30","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.cgh.2017.08.042","volume":"16","author":"S Mittal","year":"2018","unstructured":"Mittal S, Kramer JR, Omino R et al (2018) Role of age and race in the risk of hepatocellular carcinoma in veterans with hepatitis B virus infection. Clin Gastroenterol Hepatol 16(2):252\u2013259. https:\/\/doi.org\/10.1016\/j.cgh.2017.08.042","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"6082_CR31","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Int Med 151(4):264\u2013269. https:\/\/doi.org\/10.7326\/0003-4819-151-4-200908180-00135","journal-title":"Ann Int Med"},{"issue":"10","key":"6082_CR70","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1111\/jvh.13572","volume":"28","author":"JE Na","year":"2021","unstructured":"Na JE, Sinn DH, Lee JH, Jang H-J, Baek SY, Kim KA, Kang WS, Gwak G-Y, Paik YH, Kim YJ, Choi MS, Yoon J-H, Lee JH, Koh KC, Paik SW (2021) Efficacy of entecavir versus tenofovir in preventing hepatocellular carcinoma in patients with chronic hepatitis B with maintained virologic response. J Viral Hepat 28(10):1392\u20131399. https:\/\/doi.org\/10.1111\/jvh.13572","journal-title":"J Viral Hepat"},{"issue":"2","key":"6082_CR32","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1136\/gutjnl-2020-321040","volume":"70","author":"P Nathani","year":"2021","unstructured":"Nathani P, Gopal P, Rich N et al (2021) Hepatocellular carcinoma tumour volume doubling time: a systematic review and meta-analysis. Gut 70(2):401\u2013407. https:\/\/doi.org\/10.1136\/gutjnl-2020-321040","journal-title":"Gut"},{"key":"6082_CR33","doi-asserted-by":"publisher","first-page":"l2368","DOI":"10.1136\/bmj.l2368","volume":"366","author":"M Neuenschwander","year":"2019","unstructured":"Neuenschwander M, Ballon A, Weber KS et al (2019) Role of diet in type 2 diabetes incidence: umbrella review of meta-analyses of prospective observational studies. BMJ 366:l2368. https:\/\/doi.org\/10.1136\/bmj.l2368","journal-title":"BMJ"},{"issue":"12","key":"6082_CR71","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1016\/j.cgh.2020.02.046","volume":"18","author":"H Oh","year":"2020","unstructured":"Oh H, Yoon EL, Jun DW, Ahn SB, Lee HY, Jeong JY, Kim HS, Jeong SW, Kim SE, Shim JJ, Sohn JH, Cho YK; Long-Term Safety of Entecavir and Tenofovir in Patients With Treatment-Naive Chronic Hepatitis B Virus (CHB) Infection (SAINT) Study (2020) No difference in incidence of hepatocellular carcinoma in patients with chronic hepatitis B virus infection treated with entecavir vs tenofovir. Clin Gastroenterol Hepatol 18(12):2793\u20132802.e6. https:\/\/doi.org\/10.1016\/j.cgh.2020.02.046","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"6082_CR58","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.3390\/cancers14112617","volume":"14","author":"H Oh","year":"2022","unstructured":"Oh H, Lee HY, Kim J, Kim YJ (2022) Systematic review with meta-analysis: comparison of the risk of hepatocellular carcinoma in antiviral-naive chronic hepatitis B patients treated with entecavir versus tenofovir: the devil in the detail. Cancers (Basel) 14(11):2617. https:\/\/doi.org\/10.3390\/cancers14112617","journal-title":"Cancers (Basel)"},{"issue":"4","key":"6082_CR34","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","volume":"11","author":"M Omata","year":"2017","unstructured":"Omata M, Cheng AL, Kokudo N et al (2017) Asia-pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 11(4):317\u2013370. https:\/\/doi.org\/10.1007\/s12072-017-9799-9","journal-title":"Hepatol Int"},{"issue":"5","key":"6082_CR35","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1002\/hep.29320","volume":"66","author":"GV Papatheodoridis","year":"2017","unstructured":"Papatheodoridis GV, Idilman R, Dalekos GN et al (2017) The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatology 66(5):1444\u20131453. https:\/\/doi.org\/10.1002\/hep.29320","journal-title":"Hepatology"},{"issue":"5","key":"6082_CR36","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.jhep.2020.06.011","volume":"73","author":"GV Papatheodoridis","year":"2020","unstructured":"Papatheodoridis GV, Dalekos GN, Idilman R et al (2020) Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. J Hepatol 73(5):1037\u20131045. https:\/\/doi.org\/10.1016\/j.jhep.2020.06.011","journal-title":"J Hepatol"},{"issue":"1","key":"6082_CR37","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/bjc.2012.193","volume":"107","author":"EC Persson","year":"2012","unstructured":"Persson EC, Quraishi SM, Welzel TM et al (2012) Risk of liver cancer among US male veterans with cirrhosis, 1969\u20131996. Br J Cancer 107(1):195\u2013200. https:\/\/doi.org\/10.1038\/bjc.2012.193","journal-title":"Br J Cancer"},{"issue":"3","key":"6082_CR38","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/jrsm.1107","volume":"5","author":"D Pieper","year":"2014","unstructured":"Pieper D, Antoine SL, Morfeld JC, Mathes T, Eikermann M (2014) Methodological approaches in conducting overviews: current state in HTA agencies. Res Synth Methods 5(3):187\u2013199. https:\/\/doi.org\/10.1002\/jrsm.1107","journal-title":"Res Synth Methods"},{"key":"6082_CR72","first-page":"128A","volume":"70","author":"S Pol","year":"2019","unstructured":"Pol S (2019) Tenofovir versus entecavir in HBV chronic infection: impact on HCC and other liver-related complications occurrences. Hepatology 70:128A\u2013129A","journal-title":"Hepatology"},{"issue":"5","key":"6082_CR73","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1111\/apt.16197","volume":"53","author":"S Pol","year":"2021","unstructured":"Pol S, ANRS\/AFEF study group (2021) Similar 5-year HCC occurrence in Tenofovir- and Entecavir-treated HBV chronic infection in the French AFEF\/ANRS CO22 Hepather cohort. Aliment Pharmacol Ther 53(5):616\u2013629. https:\/\/doi.org\/10.1111\/apt.16197","journal-title":"Aliment Pharmacol Ther"},{"key":"6082_CR39","unstructured":"Pollock M, Fernandes RM, Becker LA, Pieper D, Hartling L (2023) Chapter V: Overviews of Reviews. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023) www.training.cochrane.org\/handbook."},{"issue":"1","key":"6082_CR40","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/mcg.0000000000001024","volume":"53","author":"A Robinson","year":"2019","unstructured":"Robinson A, Tavakoli H, Cheung R, Liu B, Bhuket T, Wong RJ (2019) Low rates of retention into hepatocellular carcinoma (HCC) surveillance program after initial HCC screening. J Clin Gastroenterol 53(1):65\u201370. https:\/\/doi.org\/10.1097\/mcg.0000000000001024","journal-title":"J Clin Gastroenterol"},{"issue":"3","key":"6082_CR41","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1136\/gutjnl-2020-323663","volume":"71","author":"V Sapena","year":"2022","unstructured":"Sapena V, Enea M, Torres F et al (2022) Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. Gut 71(3):593\u2013604. https:\/\/doi.org\/10.1136\/gutjnl-2020-323663","journal-title":"Gut"},{"issue":"6","key":"6082_CR42","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1007\/s10238-023-00990-w","volume":"23","author":"J Shao","year":"2023","unstructured":"Shao J, Wang Y, Hu L, Zhang L, Lyu C (2023) Lower risk of hepatocellular carcinoma with tenofovir than entecavir in antiviral treatment-na\u00efve chronic hepatitis B patients: a systematic review and meta-analysis involving 90,897 participants. Clin Exp Med 23(6):2131\u20132140. https:\/\/doi.org\/10.1007\/s10238-023-00990-w","journal-title":"Clin Exp Med"},{"issue":"12","key":"6082_CR43","doi-asserted-by":"publisher","first-page":"e1350","DOI":"10.1371\/journal.pone.0001350","volume":"2","author":"BJ Shea","year":"2007","unstructured":"Shea BJ, Bouter LM, Peterson J et al (2007) External validation of a measurement tool to assess systematic reviews (AMSTAR). PLoS ONE 2(12):e1350. https:\/\/doi.org\/10.1371\/journal.pone.0001350","journal-title":"PLoS ONE"},{"key":"6082_CR44","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1471-2288-7-10","volume":"7","author":"BJ Shea","year":"2007","unstructured":"Shea BJ, Grimshaw JM, Wells GA et al (2007) Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol 7:10. https:\/\/doi.org\/10.1186\/1471-2288-7-10","journal-title":"BMC Med Res Methodol"},{"issue":"10","key":"6082_CR45","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.jclinepi.2008.10.009","volume":"62","author":"BJ Shea","year":"2009","unstructured":"Shea BJ, Hamel C, Wells GA et al (2009) AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol 62(10):1013\u20131020. https:\/\/doi.org\/10.1016\/j.jclinepi.2008.10.009","journal-title":"J Clin Epidemiol"},{"key":"6082_CR46","doi-asserted-by":"publisher","first-page":"j4008","DOI":"10.1136\/bmj.j4008","volume":"358","author":"BJ Shea","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G et al (2017) AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ 358:j4008. https:\/\/doi.org\/10.1136\/bmj.j4008","journal-title":"BMJ"},{"issue":"5","key":"6082_CR74","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1007\/s10620-020-06375-3","volume":"66","author":"JW Shin","year":"2021","unstructured":"Shin JW, Jeong J, Jung SW, Lee SB, Park BR, Kim M-J, Park EJ, Park NH (2021) Comparable incidence of hepatocellular carcinoma in chronic hepatitis B patients treated with entecavir or tenofovir. Dig Dis Sci 66(5):1739\u20131750. https:\/\/doi.org\/10.1007\/s10620-020-06375-3","journal-title":"Dig Dis Sci"},{"issue":"3","key":"6082_CR47","doi-asserted-by":"publisher","first-page":"E161","DOI":"10.1111\/hepr.12743","volume":"47","author":"T Sriprayoon","year":"2017","unstructured":"Sriprayoon T, Mahidol C, Ungtrakul T et al (2017) Efficacy and safety of entecavir versus tenofovir treatment in chronic hepatitis B patients: a randomized controlled trial. Hepatol Res 47(3):E161-e168. https:\/\/doi.org\/10.1111\/hepr.12743","journal-title":"Hepatol Res"},{"issue":"2","key":"6082_CR75","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1136\/gutjnl-2019-319867","volume":"70","author":"F Su","year":"2021","unstructured":"Su F, Berry K, Ioannou GN (2021) No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir. Gut 70(2):370\u2013378. https:\/\/doi.org\/10.1136\/gutjnl-2019-319867","journal-title":"Gut"},{"issue":"6","key":"6082_CR48","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1007\/s12072-016-9745-2","volume":"10","author":"Q Tian","year":"2016","unstructured":"Tian Q, Jia J (2016) Hepatitis B virus genotypes: epidemiological and clinical relevance in Asia. Hepatol Int 10(6):854\u2013860. https:\/\/doi.org\/10.1007\/s12072-016-9745-2","journal-title":"Hepatol Int"},{"issue":"6","key":"6082_CR49","doi-asserted-by":"publisher","first-page":"e2219407","DOI":"10.1001\/jamanetworkopen.2022.19407","volume":"5","author":"DJH Tan","year":"2022","unstructured":"Tan DJH, Ng CH, Tay PWL et al (2022) Risk of hepatocellular carcinoma with tenofovir vs entecavir treatment for chronic hepatitis B virus: a reconstructed individual patient data meta-analysis. JAMA Netw Open 5(6):e2219407. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.19407","journal-title":"JAMA Netw Open"},{"issue":"4","key":"6082_CR50","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ et al (2018) Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 67(4):1560\u20131599. https:\/\/doi.org\/10.1002\/hep.29800","journal-title":"Hepatology"},{"issue":"7","key":"6082_CR76","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jfma.2016.08.006","volume":"116","author":"MC Tsai","year":"2017","unstructured":"Tsai M-C, Chen C-H, Hu T-H, Lu S-N, Lee C-M, Wang J-H, Hung C-H (2017) Long-term outcomes of hepatitis B virus-related cirrhosis treated with nucleos(t)ide analogs. J Formos Med Assoc 116(7):512\u2013521. https:\/\/doi.org\/10.1016\/j.jfma.2016.08.006","journal-title":"J Formos Med Assoc"},{"issue":"12","key":"6082_CR51","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/s2468-1253(20)30249-1","volume":"5","author":"CH Tseng","year":"2020","unstructured":"Tseng CH, Hsu YC, Chen TH et al (2020) Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 5(12):1039\u20131052. https:\/\/doi.org\/10.1016\/s2468-1253(20)30249-1","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"6082_CR52","doi-asserted-by":"publisher","first-page":"102271","DOI":"10.1016\/j.cpr.2023.102271","volume":"102","author":"S T\u00fcrk","year":"2023","unstructured":"T\u00fcrk S, Korfmacher AK, Gerger H, van der Oord S, Christiansen H (2023) Interventions for ADHD in childhood and adolescence: A systematic umbrella review and meta-meta-analysis. Clin Psychol Rev 102:102271. https:\/\/doi.org\/10.1016\/j.cpr.2023.102271","journal-title":"Clin Psychol Rev"},{"issue":"5","key":"6082_CR53","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1002\/hep.26301","volume":"58","author":"GL Wong","year":"2013","unstructured":"Wong GL, Chan HL, Mak CW et al (2013) Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 58(5):1537\u20131547. https:\/\/doi.org\/10.1002\/hep.26301","journal-title":"Hepatology"},{"issue":"7","key":"6082_CR54","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.cmi.2017.02.001","volume":"23","author":"IT Wu","year":"2017","unstructured":"Wu IT, Hu TH, Hung CH et al (2017) Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study. Clin Microbiol Infect 23(7):464\u2013469. https:\/\/doi.org\/10.1016\/j.cmi.2017.02.001","journal-title":"Clin Microbiol Infect"},{"issue":"16","key":"6082_CR55","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1093\/jnci\/djn243","volume":"100","author":"HI Yang","year":"2008","unstructured":"Yang HI, Yeh SH, Chen PJ et al (2008) Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 100(16):1134\u20131143. https:\/\/doi.org\/10.1093\/jnci\/djn243","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"6082_CR77","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1053\/j.gastro.2019.09.025","volume":"158","author":"TC Yip","year":"2020","unstructured":"Yip TC, Wong VW, Chan HL, Tse YK, Lui GC, Wong GL (2020) Tenofovir is associated with lower risk of hepatocellular carcinoma than entecavir in patients with chronic HBV infection in China. Gastroenterology 158(1):215\u2013225.e6. https:\/\/doi.org\/10.1053\/j.gastro.2019.09.025","journal-title":"Gastroenterology"},{"issue":"11","key":"6082_CR78","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1111\/jgh.15783","volume":"48","author":"JH Yu","year":"2018","unstructured":"Yu JH, Jin Y-J, Lee J-W, Lee D-H (2018) Remaining hepatocellular carcinoma risk in chronic hepatitis B patients receiving entecavir\/tenofovir in South Korea. Hepatol Res 48(11):862\u2013871. https:\/\/doi.org\/10.1111\/hepr.13194","journal-title":"Hepatol Res"},{"issue":"7","key":"6082_CR79","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1097\/MEG.0000000000001357","volume":"31","author":"JH Yu","year":"2019","unstructured":"Yu JH, Suh YJ, Jin YJ et al (2019) Prediction model for hepatocellular carcinoma risk in treatment-naive chronic hepatitis B patients receiving entecavir\/tenofovir. Eur J Gastroenterol Hepatol 31(7):865\u2013872. https:\/\/doi.org\/10.1097\/MEG.0000000000001357","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"5","key":"6082_CR56","doi-asserted-by":"publisher","first-page":"7147","DOI":"10.18632\/aging.202573","volume":"13","author":"J Yuan","year":"2021","unstructured":"Yuan J, Peng Y, Hao FB, Wang YQ, Wang CR, Zhong GC (2021) No difference in hepatocellular carcinoma risk in chronic hepatitis B patients treated with tenofovir vs entecavir: evidence from an updated meta-analysis. Aging (Albany NY) 13(5):7147\u20137165. https:\/\/doi.org\/10.18632\/aging.202573","journal-title":"Aging (Albany NY)"},{"issue":"5","key":"6082_CR57","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1111\/jgh.15783","volume":"37","author":"BH Yuan","year":"2022","unstructured":"Yuan BH, Li RH, Huo RR, Li MJ, Papatheodoridis G, Zhong JH (2022) Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated meta-analysis. J Gastroenterol Hepatol 37(5):782\u2013794. https:\/\/doi.org\/10.1111\/jgh.15783","journal-title":"J Gastroenterol Hepatol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06082-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-025-06082-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06082-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T21:29:30Z","timestamp":1741814970000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-025-06082-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,11]]},"references-count":79,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["6082"],"URL":"https:\/\/doi.org\/10.1007\/s00432-025-06082-4","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,11]]},"assertion":[{"value":"1 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval was waived by the local Ethics Committee of Qilu Hospital of Shandong University in view of the retrospective nature of the study and all the procedures being performed were part of the routine care.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate and publish"}}],"article-number":"77"}}